1. Pizzo, P.A., Poplack, D.G., Adamson, P.C., Blaney, S.M. & Helman, L. Principles and practice of pediatric oncology, xxiv, 1296 pages (Wolters Kluwer, Philadelphia, 2016).
2. Zsiros, J. et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol 14, 834-42 (2013).
3. Czauderna, P. et al. The Children's Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer 52, 92-101 (2016).
4. Koch, A. et al. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res 11, 4295-304 (2005).
5. Kurahashi, H. et al. Biallelic inactivation of the APC gene in hepatoblastoma. Cancer Res 55, 5007-11 (1995).
6. Koch, A. et al. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene. Cancer Res 59, 269-73 (1999).
7. Takayasu, H. et al. Frequent deletions and mutations of the beta-catenin gene are associated with overexpression of cyclin D1 and fibronectin and poorly differentiated histology in childhood hepatoblastoma. Clin Cancer Res 7, 901-8 (2001).
8. Taniguchi, K. et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene 21, 4863-71 (2002).
9. Aretz, S. et al. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations? Pediatr Blood Cancer 47, 811-8 (2006).
10. Cairo, S. et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 14, 471-84 (2008).
11. Eichenmuller, M. et al. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J Hepatol 61, 1312-20 (2014).
12. Sumazin, P. et al. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology 65, 104-121 (2017).
13. Grobner, S.N. et al. The landscape of genomic alterations across childhood cancers. Nature 555, 321-327 (2018).
14. Surrey, L.F., Luo, M., Chang, F. & Li, M.M. The Genomic Era of Clinical Oncology: Integrated Genomic Analysis for Precision Cancer Care. Cytogenet Genome Res 150, 162-175 (2016).
15. Arai, Y. et al. Genome-wide analysis of allelic imbalances reveals 4q deletions as a poor prognostic factor and MDM4 amplification at 1q32.1 in hepatoblastoma. Genes Chromosomes Cancer 49, 596-609 (2010).
16. Jia, D. et al. Exome sequencing of hepatoblastoma reveals novel mutations and cancer genes in the Wnt pathway and ubiquitin ligase complex. Hepatology 60, 1686-96 (2014).
17. Maschietto, M. et al. DNA methylation landscape of hepatoblastomas reveals arrest at early stages of liver differentiation and cancer-related alterations. Oncotarget 8, 97871-97889 (2017).
18. Shiraishi, Y. et al. An empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data. Nucleic Acids Res 41, e89 (2013).
19. Yamamoto, G. et al. Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. Am J Hum Genet 81, 114-26 (2007).
20. Nannya, Y. et al. A robust algorithm for copy number detection using high-density oligonucleotide single nucleotide polymorphism genotyping arrays. Cancer Res 65, 6071-9 (2005).
21. Tian, Y. et al. ChAMP: updated methylation analysis pipeline for Illumina BeadChips. Bioinformatics 33, 3982-3984 (2017).
22. Wilkerson, M.D. & Hayes, D.N. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics 26, 1572-3 (2010).
23. Sheffield, N.C. & Bock, C. LOLA: enrichment analysis for genomic region sets and regulatory elements in R and Bioconductor. Bioinformatics 32, 587-9 (2016).
24. Love, M.I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 (2014).
25. Luo, W., Friedman, M.S., Shedden, K., Hankenson, K.D. & Woolf, P.J. GAGE: generally applicable gene set enrichment for pathway analysis. BMC Bioinformatics 10, 161 (2009).
26. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28, 27-30 (2000).
27. Bonder, M.J. et al. Genetic and epigenetic regulation of gene expression in fetal and adult human livers. BMC Genomics 15, 860 (2014).
28. Camp, J.G. et al. Multilineage communication regulates human liver bud development from pluripotency. Nature 546, 533-538 (2017).
29. Traver, R.D. et al. Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). Br J Cancer 75, 69-75 (1997).
30. Kuehl, B.L., Paterson, J.W., Peacock, J.W., Paterson, M.C. & Rauth, A.M. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer 72, 555-61 (1995).
31. Kodama, Y. et al. The DDBJ Japanese Genotype-phenotype Archive for genetic and phenotypic human data. Nucleic Acids Res 43, D18-22 (2015).
32. Iwao, K. et al. Activation of the beta-catenin gene by interstitial deletions involving exon 3 in primary colorectal carcinomas without adenomatous polyposis coli mutations. Cancer Res 58, 1021-6 (1998).
33. Si-Tayeb, K., Lemaigre, F.P. & Duncan, S.A. Organogenesis and development of the liver. Dev Cell 18, 175-89 (2010).
34. Wang, X. et al. Identification of polymorphic antioxidant response elements in the human genome. Hum Mol Genet 16, 1188-200 (2007).
35. Siegel, D., Yan, C. & Ross, D. NAD(P)H:quinone oxidoreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 83, 1033-40 (2012).
36. Li, Z. et al. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers. BMC Cancer 15, 207 (2015).
37. Yang, Y. et al. Clinical implications of high NQO1 expression in breast cancers. J Exp Clin Cancer Res 33, 14 (2014).
38. Asher, G., Bercovich, Z., Tsvetkov, P., Shaul, Y. & Kahana, C. 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1. Mol Cell 17, 645-55 (2005).
39. Wilson, V.L., Smith, R.A., Ma, S. & Cutler, R.G. Genomic 5-methyldeoxycytidine decreases with age. J Biol Chem 262, 9948-51 (1987).
40. Bjornsson, H.T. et al. Intra-individual change over time in DNA methylation with familial clustering. JAMA 299, 2877-83 (2008).
41. Tawa, R. et al. Methylated cytosine level in human liver DNA does not decline in aging process. Mech Ageing Dev 62, 255-61 (1992).
42. Fagerholm, R. et al. NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 40, 844-53 (2008).
43. Kolesar, J.M. et al. The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncol Rep 25, 1765-72 (2011).
44. Anwar, A. et al. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems. J Biol Chem 278, 10368-73 (2003).
45. Asher, G., Lotem, J., Kama, R., Sachs, L. & Shaul, Y. NQO1 stabilizes p53 through a distinct pathway. Proc Natl Acad Sci U S A 99, 3099-104 (2002).
46. Rada, P. et al. WNT-3A regulates an Axin1/NRF2 complex that regulates antioxidant metabolism in hepatocytes. Antioxid Redox Signal 22, 555-71 (2015).
47. Koomoa, D.L. et al. DFMO/eflornithine inhibits migration and invasion downstream of MYCN and involves p27Kip1 activity in neuroblastoma. Int J Oncol 42, 1219-28 (2013).